Tarsus officer plans $906K stock sale under Rule 144

Tarsus Pharmaceuticals, Inc. (TARS) has an officer, Bobak Azamian, filing a Form 144 notice covering a potential sale of up to 10,000 shares of common stock through Merrill Lynch on Nasdaq.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) has an officer, Bobak Azamian, filing a Form 144 notice covering a potential sale of up to 10,000 shares of common stock through Merrill Lynch on Nasdaq. These shares were acquired on January 13, 2017 in a private placement. In the prior three months, the Bobak Azamian Living Trust reported two sales of 10,000 shares each.

Key Figures

Shares covered by Form 144: 10,000 shares Aggregate market value of shares to be sold: $905,587.08 Shares outstanding: 43,882,996 shares +3 more

6 metrics

Shares covered by Form 144 10,000 shares Maximum number of Tarsus Pharmaceuticals, Inc. common shares in the new Form 144 notice

Aggregate market value of shares to be sold $905,587.08 Market value of the 10,000 TARS shares covered by the Form 144

Shares outstanding 43,882,996 shares Tarsus Pharmaceuticals, Inc. common shares outstanding as referenced in the Form 144

Recent sale on June 17, 2026 10,000 shares for $615,473.27 Sale by the Bobak Azamian Living Trust in the past three months

Recent sale on September 2, 2026 10,000 shares for $800,568.71 Second sale by the Bobak Azamian Living Trust in the past three months

Acquisition date of shares in notice January 13, 2017 Date the 10,000 TARS shares were acquired in a private placement

Key Terms

Rule 144, private placement, living trust, Form 144

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

private placement financial

"COMMON | 01/13/2017 | PRIVATE PLACEMENT | TARSUS PHARMACEUTICALS INC"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

living trust financial

"BOBAK AZAMIAN LIVING TRUST 17700 LAGUNA CANYON ROAD FL 4"

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

What does the Form 144 filing for TARS disclose?

It discloses that officer Bobak Azamian has filed a notice under Rule 144 covering a potential sale of up to 10,000 shares of Tarsus Pharmaceuticals, Inc. common stock through Merrill Lynch on Nasdaq.

How many TARS shares are covered by the new Form 144 and what is their value?

The notice covers up to 10,000 shares of TARS common stock with an aggregate market value of about $905,587.08, as indicated in the Form 144 securities information section.

When and how were the TARS shares in this Form 144 originally acquired?

The 10,000 TARS shares covered by this notice were acquired on January 13, 2017 in a private placement of Tarsus Pharmaceuticals, Inc. common stock.

What TARS share sales has the Bobak Azamian Living Trust reported in the past three months?

The Bobak Azamian Living Trust reported selling 10,000 shares of TARS common stock on June 17, 2026 for $615,473.27 and another 10,000 shares on September 2, 2026 for $800,568.71.

How many TARS shares are outstanding according to this Form 144?

The Form 144 lists 43,882,996 shares of Tarsus Pharmaceuticals, Inc. common stock as outstanding, providing context for the relative size of the 10,000 shares covered by the notice.

Through which broker is the TARS Form 144 sale planned?

The Form 144 identifies Merrill Lynch, located in Newport Beach, California, as the broker for the potential sale of up to 10,000 TARS common shares on Nasdaq.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 05:25 PM Accepted by SEC EDGAR 09/04/2026 - 05:23 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001827672
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TARSUS PHARMACEUTICALS INC
SEC File Number	001-39614
Address of Issuer	17700 LAGUNA CANYON ROAD FL 4 IRVINE CALIFORNIA 92618
Phone	949-418-1801
Name of Person for Whose Account the Securities are To Be Sold	BOBAK AZAMIAN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	MERRILL LYNCH 520 NEWPOR CENTER DRIVE 20TH FLOOR NEWPORT BEACH CA 92660	10000	905587.08	43882996	09/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	01/13/2017	PRIVATE PLACEMENT	TARSUS PHARMACEUTICALS INC			10000	01/13/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
BOBAK AZAMIAN LIVING TRUST 17700 LAGUNA CANYON ROAD FL 4 IRVINE CA 92618	COMMON	06/17/2026	10000	615473.27
BOBAK AZAMIAN LIVING TRUST 17700 LAGUNA CANYON ROAD FL 4 IRVINE CA 92618	COMMON	09/02/2026	10000	800568.71

144: Remarks and Signature

Remarks	THIS TRANSACTION TOOK PLACE IN THE BOBAK AZAMIAN LIVING TRUST BOBAK AZAMIAN TRUSTEE
Date of Notice	09/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	BOBAK AZAMIAN
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)